

Mike Dinger, MD
March 5, 2016



◆ Depressive, Anxiety, and Bipolar

◆ Personality Disorders

◆ ADHD

◆ Discuss changes from DSM-IV to DSM-5

- ◆ Axis I: Clinical Syndromes (Depression, Anxiety, OCD, Bipolar)
- ◆ Axis II: Developmental and Personality Disorders (includes Autism and Mental Retardation)
- ◆ Axis III: General Medical Conditions (that play a role in the development, exacerbation, or continuance of Axis I and II)
- ◆ Axis IV: Psychosocial and Environmental Problems (that impact Axis I and II)
- ◆ Axis V: Global Assessment of Functioning (scale 0-100; less than 50 often considered significant impairment)

◆ ~~Axis I: Clinical Syndromes (Depression, Anxiety, OCD, Bipolar)~~

◆ ~~Axis II: Developmental and Personality Disorders (includes Autism and Mental Retardation)~~

◆ ~~Axis III: General Medical Conditions (that play a role in the development, exacerbation, or continuance of Axis I and II)~~

◆ ~~Axis IV: Psychosocial and Environmental Problems (that impact Axis I and II)~~

◆ ~~Axis V: Global Assessment of Functioning (scale 0-100; less than 50 often considered significant impairment)~~

🟢 No more Multiaxial Assessment

◆ Major Depressive Disorder

◆ Approximately 5% of population

◆ Female to male 2:1

◆ 5 of the following for at least 2 weeks duration, of which one is Depressed mood or Loss of interest:

◆ *Depressed mood

◆ Sleep disturbance

◆ *Loss of Interest (Anhedonia)

◆ Guilt/worthlessness

◆ Fatigue/loss of Energy

◆ Difficulty Concentrating

◆ Appetite/Change in weight

◆ Psychomotor agitation/retardation

◆ Thoughts of death or Suicide (with or without plan)

◆ All antidepressants have similar efficacy, but different side effect profiles

◆ TCA's (Imipramine, Amitriptyline): Anticholinergic, QT prolongation.

◆ Mirtazapine causes weight gain and somnolence.

◆ SSRI's: Sexual side effects, Weight gain (Paroxetine the worst), QT prolongation (Citalopram).

◆ Less side effects with SNRI's (Venlafaxine, Duloxetine) and Bupropion

◆ SSRI first line therapy in most situations

◆ Black Box Warning: Increased risk of suicidal thoughts or behaviors in children, adolescents, and young adults on SSRI's

◆ Fluoxetine only SSRI that is FDA approved in children/adolescents (ages 8 and older)

◆ Push the dose prior to switching to different agent

◆ Can augment with Bupropion, Lithyronine (T3 Cytomel)

◆ There is a role for cognitive-behavioral therapy

◆ Electroconvulsive Therapy is an option in refractory depression (memory loss is short-term)

◆ Combines what was formerly termed “Dysthymia” plus Chronic Major Depression

◆ Depressed mood is present for most of the day, more days than not and depression has been present for at least two years without a two month hiatus.

◆ Persistent and pervasive



- ◆ 70% of new moms have “Baby Blues”
- ◆ Mild symptoms that resolve within 10 days
- ◆ 10-20% have Post-Partum Depression
- ◆ 40% recurrence rate with subsequent pregnancies
- ◆ Lots of morbidity for mom and baby
- ◆ Screen at post-partum check and at 2 month WCC
- ◆ Family physician often in best position to screen, diagnose, and treat

◆ In most patient types, screening is recommended IF adequate resources exist to deal with further diagnosis and treatment.

◆ Panic Disorder: Recurrent panic attacks during which four of the following symptoms begin abruptly and reach a peak within 10 minutes in the presence of intense fear:

◆ Palpitations

◆ Sweating

◆ Trembling/shaking

◆ SOB

◆ Choking sensation

◆ Chest pain/discomfort

- ◆ Nausea
- ◆ Dizziness
- ◆ Derealization/Depersonalization
- ◆ Fear of losing control or going crazy
- ◆ Fear of dying
- ◆ Paresthesias
- ◆ Chills/Hot flushes

💧 Treatment:

💧 SSRI's

💧 prn Benzodiazepines

💧 Cognitive behavioral therapy

◆ Generalized Anxiety Disorder

◆ Unrealistic or excessive anxiety or worry about two or more life circumstances for at least six months

◆ Most common anxiety disorder

◆ Medications (Buspirone, Antidepressants, prn Benzodiazepines) + Cognitive behavioral therapy

◆ 2-5% of population

◆ Bipolar I

◆ One or more Manic episodes

◆ Commonly accompanied by a history of at least one major depressive episode

◆ Bipolar II

◆ One or more major depressive episodes with at least one hypomanic episode

◆ Cyclothymia

◆ Hypomania and depression (below criteria for MDD)

◆ Treatment

◆ Lithium

◆ Anticonvulsants

◆ Valproic Acid, Carbamazepine, Lamotrigine, Oxcarbazepine

◆ Atypical antipsychotics

•An enduring pattern of inner experience and behavior that deviates markedly from the expectations of the individual's culture. This pattern is manifested in two (or more) of the following areas:

–cognition (i.e., ways of perceiving and interpreting self, other people, and events)

–affectivity (i.e., the range, intensity, lability, and appropriateness of emotional response)

–interpersonal functioning

- The enduring pattern is inflexible and pervasive across a broad range of personal and social situations.
- The enduring pattern leads to clinically significant distress or impairment in social, occupational, or other important areas of functioning.

Cluster A

Paranoid

Schizoid

Schizotypal

Cluster B

Antisocial

Borderline

Histrionic

Narcissistic

Cluster C

OCPD

Dependent

Avoidant

Odd

Paranoid

Schizoid

Schizotypal

Erratic

Antisocial

Borderline

Histrionic

Narcissistic

Anxious

OCPD

Dependent

Avoidant

Weirdo's

Paranoid

Schizoid

Schizotypal

Wankers

Antisocial

Borderline

Histrionic

Narcissistic

Weanies

OCPD

Dependent

Avoidant

◆ Schizoid vs. Schizotypal

◆ Schizoid: Solitary, indifferent to praise/criticism, low functioning, premorbid condition to schizophrenia?

◆ Schizotypal: Magical thinking, ideas of reference, eccentric behavior and appearance.

◆ Antisocial

◆ Cruel to animals as child, Unlawful activity as adolescent/adult, Can't hold a job

◆ Irresponsible, Deceitful, Unremorseful

◆ Histrionic

◆ Exaggerate expression of emotions, uses superlatives, attention seeking

◆ Treatment: In general, no medication or therapy that is helpful

◆ 2-16% of school age children

◆ Child must display 6 of 9 symptoms of inattention, or 6 of 9 symptoms of impulsivity/hyperactivity

◆ Must be present for more than 6 months

◆ Must begin before age 12*

◆ Must occur in more than 1 setting (home and school)

💧 Inattention

- 💧 Often fails to give close attention to details or makes careless mistakes in schoolwork, work, or other activities
- 💧 Often has difficulty sustaining attention to tasks or play activities
- 💧 Often does not listen when spoken to directly
- 💧 Often does not follow through on instructions and fails to finish schoolwork, chores, or duties in the workplace
- 💧 Often has difficulty organizing tasks and activities

💧 Inactivity

- 💧 Often avoids, dislikes, or is reluctant to engage in tasks that require sustained mental effort (homework)
- 💧 Often loses things necessary for tasks or activities
- 💧 Is often easily distracted by extraneous stimuli
- 💧 Is often forgetful in daily activities

◆ Hyperactivity

- ◆ Often fidgets with hands or feet, or squirms in seat
- ◆ Often leaves seat in classroom or in other situations in which remaining seated is expected
- ◆ Often runs about or climbs excessively in situation in which it is inappropriate
- ◆ Often has difficulty playing or engaging in leisure activities quietly
- ◆ Is often “on the go” or acts as if “driven by a motor”

◆ Impulsivity

◆ Often blurts out answers before questions have been completed

◆ Often has difficulty awaiting turn

◆ Often interrupts or intrudes on others (butts in on conversations)

- ◆ Diagnose with Rating Scales, filled out by parents and teachers (Connors, Vanderbilt, etc.)
- ◆ Treat with medications
- ◆ Stimulants first line
- ◆ Atomoxetine (Strattera) second line
- ◆ Medication + Behavioral therapy = Medication alone
- ◆ But with combination therapy may be able to use lower dose of

◆ Childhood ADHD persists into adulthood 30% of the time

◆ Diagnostic criteria are the same, except only need 5 of 9 symptoms

◆ Also use Rating Scales, but ones that are unique for adult ADHD (i.e. Wender Utah Rating Scale)

◆ Stimulants and Atomoxetine (Strattera) first line

◆ Antidepressants second line

◆ American Psychiatric Association. Highlights of Changes from DSM-IV-TR to DSM-5; 2013

◆ Hahn RN, Albers LJ, Reist C. Current Clinical Strategies: Psychiatry. Laguna Hills, CA: Current Clinical Strategies; 1997

◆ Michels TC, Tiu AY, Graver CJ: Neuropsychological evaluation in primary care. *Am Fam Physician* 2010;82(5): 495-502.

◆ Little A: Treatment-resistant depression. *Am Fam Physician* 2009;80(2):167-172.

◆ Gartlehner G, Hansen RA, Morgan LC, et al: Comparative benefits and harms of second-generation antidepressants for

◆ Carvalho AF, Cavalcante JL, Castelo MS, Lima MC: Augmentation strategies for treatment-resistant depression: a literature review. *J Clin Pharm Ther*. 2007 Oct;32(5):415-28.

◆ Loganathan M, Lohano K, Roberts RJ, et al: When to suspect bipolar disorder. *J Fam Pract* 2010;59(12):682-688.

◆ Rader R, McCauley L, Callen EC: Current strategies in the diagnosis and treatment of childhood attention-deficit/hyperactivity disorder. *Am Fam Physician* 2009;79(8):657-665.

◆ Post R E, McCauley L, Kuransik SL: Diagnosis and management of attention-deficit/hyperactivity disorder in adults. *Am Fam Physician* 2012;85(9):890-896.

◆ National Institutes of Health National Institutes of Mental Health: Antidepressant Medications for Children and